(Reuters) -Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.
On an adjusted basis, Biogen expects 2025 adjusted per-share profit between $15.50 and $16.00, compared with its previous forecast of between $14.50 and $15.50.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Comments